[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542201":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":34,"responsibleParty":40,"collaborators":26,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":26,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":26,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":26,"overallStatus":61,"whyStopped":26,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Handok Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HD-P023","EXPERIMENTAL","One tablet of HD-P023 by oral",[13],"Drug: HD-P023",{"label":15,"type":16,"description":17,"interventionNames":18},"Co-administration of Teneligliptin and Empagliflozin High","ACTIVE_COMPARATOR","One tablet each of Teneligliptin and Empagliflozin High by oral",[19,20],"Drug: Teneligliptin","Drug: Empagliflozin",[22,27,31],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Single dose administration of HD-P023",[9],null,{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Teneligliptin","Single does administration of Teneligliptin and Empagliflozin High",[15],{"type":23,"name":32,"description":29,"armGroupLabels":33,"otherNames":26},"Empagliflozin",[15],[35],{"facility":36,"status":26,"city":37,"state":38,"zip":26,"country":39,"countryCode":26,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Central Hospital","Siheung-si","Gyeonggi-do","South Korea",{"type":41,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100542201","phase-1-pharmacokinetics-of-hd-p023-and-co-administration-of-teneligliptin-and-empagliflozin-high-in-healthy-volunteers-100542201",false,"NCT06339788","Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","Inclusion Criteria:\n\n* Patients who are 19 years or older on screening\n* Signed informed consent\n* Healthy Volunteer\n* Other inclusion applies\n\nExclusion Criteria:\n\n* Clinically relevant\u002Fsignificant findings as evaluated by the investigator\n* Other exclusion applied",true,"ALL","19 Years",{"count":53,"type":54},40,"ACTUAL","INTERVENTIONAL",[57],"PHASE1","The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers",[60],"Healthy Volunteers","COMPLETED","2025-02-03",{"date":64,"type":54},"2025-02-04",{"date":66,"type":54},"2024-05-10",{"date":68,"type":54},"2024-06-12",{"name":5,"class":6},1]